Department of Medical Microbiology and Clinical Microbiology, Faculty of Medicine, Near East University, Nicosia, Cyprus.
Department of Pediatrics, Division of Allergy and Immunology, Faculty of Medicine, Near East University, Nicosia, Cyprus.
Clin Exp Immunol. 2022 Sep 29;209(3):262-269. doi: 10.1093/cei/uxac075.
Allergic respiratory diseases (ARDs) are still a major burden on global public health. Sublingual immunotherapy (SLIT) is a mode of allergen immunotherapy (AIT) which involves administration of the allergen under the tongue, and benefits from tolerogenic properties of the oral mucosa. Studies revealed reduced levels of eosinophilia and eosinophil-dominated inflammation in airways of both animals and humans after SLIT. SLIT was also suggested to lower basophil responsiveness and innate lymphoid cell-2 function in blood samples collected from patients with ARD. Moreover, apart from shifting pathogenic type 2 (TH2) to a type 1 (TH1) and protective regulatory (Treg) polarization of helper T-cell immune response, antibody isotype switch from IgE to IgG1, IgG2, IgG4 and IgA was also reported in patients with ARD receiving SLIT. Today, the literature on SLIT-mediated activities is still scarce and more studies are required to further enlighten the mechanisms utilized by SLIT for the induction of tolerance. The aim of this review is to summarize the current knowledge about the immune-regulatory mechanisms induced by SLIT against ARDs.
变应性呼吸道疾病(ARDs)仍然是全球公共卫生的主要负担。舌下免疫疗法(SLIT)是一种过敏原免疫疗法(AIT)模式,涉及在舌下给予过敏原,并受益于口腔黏膜的耐受特性。研究表明,SLIT 后动物和人类气道中的嗜酸性粒细胞增多和嗜酸性粒细胞为主的炎症减少。SLIT 还被认为可以降低 ARD 患者血液样本中嗜碱性粒细胞的反应性和先天淋巴细胞-2 功能。此外,除了将致病性 2 型(TH2)转变为 1 型(TH1)和保护性调节(Treg)辅助 T 细胞免疫反应极化外,接受 SLIT 的 ARD 患者的抗体同种型也从 IgE 转换为 IgG1、IgG2、IgG4 和 IgA。如今,关于 SLIT 介导的活性的文献仍然很少,需要更多的研究来进一步阐明 SLIT 用于诱导耐受的机制。本综述的目的是总结目前关于 SLIT 诱导对 ARD 的免疫调节机制的知识。